ELDN - NASDAQ
Eledon Pharmaceuticals, Inc.
$3.53
+6.0%Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
At a Glance
Live Snapshoteldn
Selling, General and Administrative Expenses
Last Annual Value
16.98M
3-Year CAGR
11%
5-Year CAGR
20%
10-Year CAGR
3%
Eledon Pharmaceuticals, Inc. Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Eledon Pharmaceuticals, Inc. NASDAQ:ELDN | 16.98M | 11.3% | 5.6% | 2.6% | |
 Entrada Therapeutics, Inc. NASDAQ:TRDA | 41.05M | 8.3% | 22.0% | N/A | |
 Humacyte, Inc. NASDAQ:HUMA | 31.17M | 15.2% | 8.1% | N/A | |
 Atea Pharmaceuticals, Inc. NASDAQ:AVIR | 32.86M | -13.0% | -6.4% | N/A | |
 Actuate Therapeutics Inc NASDAQ:ACTU | 12.20M | 55.2% | N/A | N/A | |
 Applied Therapeutics, Inc. NASDAQ:APLT | 56.01M | 39.5% | 5.4% | N/A | |
 Avalo Therapeutics, Inc. NASDAQ:AVTX | 22.90M | 30.5% | -1.5% | 12.5% | |
 Elicio Therapeutics, Inc. NASDAQ:ELTX | 12.81M | 2.5% | -6.3% | N/A | |
 Fate Therapeutics, Inc. NASDAQ:FATE | 46.52M | -21.7% | -4.1% | 16.7% | |
 Seres Therapeutics, Inc. NASDAQ:MCRB | 39.16M | -20.4% | -10.8% | 1.8% | |
 Nkarta, Inc. NASDAQ:NKTX | 31.57M | -3.3% | 6.5% | N/A |
Eledon Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your ELDN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.